AstraZeneca topped off a very busy week with the company’s first-quarter 2022 financial report, citing a total of $11.39 billion in revenue, a whopping increase of 60 percent. That performance was driven by the acquisition of Alexion and several contracts for Vaxzevria, AstraZeneca’s COVID-19 vaccine developed with the University of Oxford.
CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.
When AstraZeneca announced plans to move from Alderley Park to Cambridge, U.K., in 2013, the new building was expected to cost £330 million. Now that has expanded to £1 billion (about $1.3 billion), three times the original estimate.
Adaptive Biotechnologies announced plans to lease a new corporate headquarters, tripling the company’s footprint in Seattle.
Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
Cerecor Inc. announced that the company moved its U.S. corporate offices to Rockville, Maryland after previously being based in Baltimore.
Daggerwing Group Inc. announces a move of the company’s New York operations from 250 Greenwich Street to the heart of SoHo at 536 Broadway.
TELFORD, Pa.–(BUSINESS WIRE)–Secant Medical® announced today the corporate headquarters have moved to 551 East Church Avenue, Telford, Pennsylvania 18969 from its long time Perkasie location. The company has been investing […]